Symphogen
Michael Herbst has a diverse work experience in finance and accounting roles. Michael is currently the Director of Finance at Symphogen, a position they started in March 2023. Prior to this, Michael worked at Ferring Pharmaceuticals from 2017 to 2023, where they held roles such as Accounting & Reporting Manager and Finance Manager. From 2011 to 2017, they were the Finance Manager at Ferrosan Medical Devices A/S, responsible for consolidation, reporting, and financial optimization. Before that, Michael worked at Stryhns Gruppen A/S from 2009 to 2011, serving as Finance Manager and Business Controller. Their earliest work experience was at Nordisk Film where they worked as a Business Controller from 2002 to 2008, providing financial reporting and analysis for Nordisk Film Interaktiv.
Michael Herbst completed their education at the Copenhagen Business School from 2000 to 2004, where they earned a Bachelor of Business Administration (BBA) degree with a specialization in Accounting. Before that, from 1989 to 1992, they attended Køge Handelsskole, where they pursued Business study, focusing on Basic finance & accounting.
Symphogen
3 followers
Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities. Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.